We are a pioneering, clinical-stage, metabolic oncology therapeutics company, focused on transforming the lives of patients with hard to treat cancers by applying our deep understanding of the unique bio-energetic processes specific to cancer. Our research in the field of altered cancer metabolism directed therapies has led to the discovery of novel, first-in-class drugs and drug delivery technologies that have the potential to revolutionize cancer treatment. Our primary objective is to produce highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues. By attacking regulatory processes that are unique to cancer and not found in healthy cells we aim to significantly improve the safety profile and efficacy of cancer treatment. CPI-613, the lead drug from our Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. CPI-613 is currently being evaluated in multiple Phase I, I/II, and II clinical studies as a single agent, as well as in combination with standard drug therapy.